GeneDx (NASDAQ:WGS) CEO Katherine Stueland Sells 46,933 Shares

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 46,933 shares of GeneDx stock in a transaction on Thursday, March 26th. The shares were sold at an average price of $63.17, for a total value of $2,964,757.61. Following the sale, the chief executive officer directly owned 91,514 shares in the company, valued at $5,780,939.38. The trade was a 33.90% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Katherine Stueland also recently made the following trade(s):

• On Monday, March 16th, Katherine Stueland sold 17,179 shares of GeneDx stock. The stock was sold at an average price of $76.80, for a total value of $1,319,347.20.
• On Wednesday, March 4th, Katherine Stueland sold 25,459 shares of GeneDx stock. The shares were sold at an average price of $78.61, for a total value of $2,001,331.99.
• On Thursday, January 29th, Katherine Stueland sold 1,653 shares of GeneDx stock. The shares were sold at an average price of $94.00, for a total transaction of $155,382.00.

GeneDx Price Performance

WGS traded up $0.13 on Thursday, reaching $65.65. The company had a trading volume of 56,819 shares, compared to its average volume of 761,160. The company has a market capitalization of $1.92 billion, a P/E ratio of -87.74 and a beta of 2.17. The company has a current ratio of 2.46, a quick ratio of 2.34 and a debt-to-equity ratio of 0.16. The company has a fifty day moving average of $83.17 and a 200-day moving average of $115.33. GeneDx Holdings Corp. has a one year low of $55.17 and a one year high of $170.87.

GeneDx (NASDAQ:WGS) last released its quarterly earnings results on Monday, February 23rd. The company reported $0.14 EPS for the quarter, topping analysts’ consensus estimates of $0.11 by $0.03. The company had revenue of $120.99 million for the quarter, compared to the consensus estimate of $120.80 million. GeneDx had a negative net margin of 4.92% and a positive return on equity of 14.73%. As a group, equities research analysts anticipate that GeneDx Holdings Corp. will post 0.97 earnings per share for the current year.

Hedge Funds Weigh In On GeneDx

A number of institutional investors have recently bought and sold shares of WGS. Kestra Advisory Services LLC purchased a new stake in GeneDx during the fourth quarter valued at about $27,000. Jones Financial Companies Lllp raised its holdings in shares of GeneDx by 664.3% during the third quarter. Jones Financial Companies Lllp now owns 214 shares of the company’s stock valued at $25,000 after acquiring an additional 186 shares during the period. Ramirez Asset Management Inc. purchased a new stake in shares of GeneDx in the 4th quarter valued at approximately $33,000. Greenline Wealth Management LLC purchased a new stake in shares of GeneDx in the 4th quarter valued at approximately $33,000. Finally, Bank Julius Baer & Co. Ltd Zurich acquired a new position in GeneDx in the 4th quarter worth approximately $35,000. Hedge funds and other institutional investors own 61.72% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Weiss Ratings reaffirmed a “sell (d)” rating on shares of GeneDx in a research note on Wednesday, January 21st. Canaccord Genuity Group raised their target price on GeneDx from $160.00 to $170.00 and gave the company a “buy” rating in a research note on Monday, December 22nd. Piper Sandler reiterated an “overweight” rating and issued a $130.00 price target (down from $160.00) on shares of GeneDx in a research report on Tuesday, February 24th. BTIG Research cut their price target on shares of GeneDx from $200.00 to $170.00 and set a “buy” rating for the company in a report on Tuesday, February 24th. Finally, Guggenheim reduced their price objective on shares of GeneDx from $170.00 to $100.00 and set a “buy” rating for the company in a research report on Monday. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $140.71.

GeneDx Company Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.